Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
GoldInxs Mining Corp. Closes Second Tranche of Upsized Non-Brokered Private Placement and Announces Board Changes